Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000551939 | SCV000645557 | uncertain significance | PTEN hamartoma tumor syndrome | 2017-07-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with PTEN-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces cysteine with phenylalanine at codon 71 of the PTEN protein (p.Cys71Phe). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and phenylalanine. |
Ambry Genetics | RCV001014557 | SCV001175278 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-01-17 | criteria provided, single submitter | clinical testing | The p.C71F variant (also known as c.212G>T), located in coding exon 4 of the PTEN gene, results from a G to T substitution at nucleotide position 212. The cysteine at codon 71 is replaced by phenylalanine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV001014557 | SCV001356968 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-06-21 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000551939 | SCV004838541 | uncertain significance | PTEN hamartoma tumor syndrome | 2023-05-08 | criteria provided, single submitter | clinical testing | |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV004554806 | SCV005043921 | pathogenic | PTEN-related disorder | 2024-03-15 | criteria provided, single submitter | clinical testing | PS2, PM1, PM2, PP2, PP3 |
Mayo Clinic Laboratories, |
RCV004791555 | SCV005412167 | uncertain significance | not provided | 2024-07-16 | criteria provided, single submitter | clinical testing | PP2, PP3, PM2, PM5 |